Given the availability of disease-modifying drugs, the diagnostic journey of SMA should be well established with neonatal screening [44] as well as screening for C9Orf72 expansion and at least SOD1, FUS, and TARDBP SNV for all new ALS patients [45, 46] (Fig. 4). Here, TARDBP is linked to proximal spinal muscular atrophy.